Rosuvastatin

• High Cholesterol
• Cardiovascular Disease Prevention
• Familial Hypercholesterolemia
• Atherosclerosis

Rosuvastatin (brand name Crestor) is one of the most potent HMG-CoA reductase inhibitors available, capable of reducing LDL cholesterol by 45 to 55 percent at higher doses. It is approved for primary hyperlipidemia, mixed dyslipidemia, hypertriglyceridemia, familial hypercholesterolemia, slowing atherosclerosis progression, and primary prevention of cardiovascular disease in selected adults with elevated inflammatory markers. For patients with established atherosclerotic cardiovascular disease, diabetes mellitus, or significantly elevated 10-year cardiovascular risk, rosuvastatin is one of the two preferred high-intensity statins, alongside atorvastatin. Generic versions are widely available and inexpensive, making it accessible for the long-term treatment most patients require.

Mechanism of Action

Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis. By blocking the conversion of HMG-CoA to mevalonate, the drug forces the liver to compensate for reduced intracellular cholesterol by upregulating LDL receptors on the hepatocyte surface. More LDL receptors clear more LDL particles from circulation, lowering plasma LDL cholesterol and to a lesser degree triglycerides and apolipoprotein B, while modestly raising HDL cholesterol. The magnitude of LDL reduction is dose-dependent: roughly 45 percent at 10 mg, 52 percent at 20 mg, and 55 percent at 40 mg.

Beyond its lipid-lowering effects, rosuvastatin produces pleiotropic benefits that include improved endothelial function, reduced vascular inflammation as evidenced by lower high-sensitivity C-reactive protein, plaque stabilization with possible regression of atheroma volume, and reduced platelet reactivity. The JUPITER trial demonstrated that rosuvastatin 20 mg in patients with normal LDL but elevated hs-CRP cut major cardiovascular events nearly in half. These cumulative effects underpin the American Heart Association and ACC guideline recommendations for high-intensity statin therapy in established atherosclerotic disease, primary prevention with significantly elevated risk, and most patients with diabetes between ages 40 and 75. Rosuvastatin is hydrophilic, less protein-bound, and minimally metabolized by CYP3A4 - features that distinguish it from simvastatin and lovastatin and reduce certain drug interactions. It is primarily eliminated unchanged in feces via OATP1B1 hepatic uptake and biliary excretion, with about 10 percent renal clearance. Genetic variants in OATP1B1 transporters can produce up to twofold higher exposure in some patients, which partly explains the increased systemic exposure seen in Asian patients and underlies the lower starting doses recommended for that population.

Clinical Use

For secondary prevention after coronary artery disease, stroke, or peripheral arterial disease, the goal is high-intensity statin therapy that produces at least a 50 percent LDL reduction. Both rosuvastatin 20 to 40 mg and atorvastatin 40 to 80 mg achieve this. Choice between them often comes down to interaction profile, cost, and patient tolerance. Rosuvastatin is favored when the patient takes drugs that strongly affect CYP3A4, when atorvastatin has caused intolerable myalgias, or when an Asian patient requires lower starting doses due to ethnic differences in drug metabolism that increase rosuvastatin exposure roughly twofold.

For primary prevention, USPSTF and ACC/AHA guidelines support statin therapy in adults aged 40 to 75 with at least one cardiovascular risk factor and a 10-year ASCVD risk of 7.5 percent or higher; rosuvastatin 10 to 20 mg is a typical choice. Patients with familial hypercholesterolemia frequently require maximum-tolerated rosuvastatin plus ezetimibe and sometimes a PCSK9 inhibitor to reach LDL goals. Compared with pravastatin and simvastatin, rosuvastatin offers significantly greater LDL reduction, making it the preferred high-intensity option. Patient selection prioritizes those with established disease, diabetes, very high LDL, or elevated calculated risk; baseline counseling about expected myalgia, the small but real diabetes risk, and lifelong duration is essential. For lifestyle context, see our article on understanding cholesterol - good, bad, and what to do and the broader landscape of statin therapy in our cholesterol medications guide. Patients with active liver disease, prior immune-mediated necrotizing myopathy, or pregnancy are not candidates.

How to Take It

Rosuvastatin is taken once daily at any time of day - morning or evening - with or without food. Unlike simvastatin and lovastatin, which work best at bedtime because of nighttime hepatic cholesterol synthesis, rosuvastatin's longer half-life makes timing flexible. Tablets are swallowed whole with water. Aluminum- or magnesium-containing antacids should be separated from rosuvastatin by at least two hours because they reduce absorption. If a dose is missed and remembered within 12 hours, take it; if not, skip and resume the next day - never double up.

The first one to two weeks may bring mild myalgia, headache, or gastrointestinal upset; these usually fade. New muscle pain that is severe, accompanied by weakness, dark urine, or fever, should prompt immediate evaluation for rhabdomyolysis. Maintaining adequate hydration and avoiding heavy unaccustomed exertion in the first weeks reduces myalgia risk. Statin therapy is typically lifelong; stopping abruptly returns LDL to pre-treatment levels within weeks and erases cardiovascular benefit. Store tablets at room temperature. Grapefruit juice does not significantly affect rosuvastatin (unlike simvastatin and atorvastatin), but moderation is reasonable. Patients who notice persistent fatigue, brain fog, or memory complaints should not silently stop the drug; switching statins, lowering the dose, or trying every-other-day dosing often resolves nuisance side effects while preserving cardiovascular protection.

Monitoring and Follow-Up

A fasting lipid panel is checked at baseline and again 4 to 12 weeks after starting or after any dose change. The treatment goal is at least a 50 percent LDL reduction for high-intensity therapy or 30 to 49 percent for moderate-intensity therapy. Once stable, annual lipid checks suffice. A baseline ALT is obtained; routine repeat liver enzyme monitoring is no longer required by the FDA for asymptomatic patients but is reasonable annually or with new symptoms. Creatine kinase is checked only when muscle pain or weakness occurs - routine CK monitoring is not recommended.

For patients on the 40 mg dose, baseline serum creatinine and a urine dipstick for proteinuria are reviewed; the higher dose has been associated with low-grade proteinuria and hematuria. Hemoglobin A1c may rise modestly with statin therapy, and clinicians weigh the small absolute increase in diabetes risk against substantial cardiovascular benefit, particularly in patients with prediabetes; see our prediabetes reversal guide for management context. Thyroid function should be checked if myalgia develops, since untreated hypothyroidism amplifies statin myopathy. Vitamin D deficiency is also worth screening because supplementation may improve statin tolerance in some patients with myalgia. Drug interactions, particularly cyclosporine and gemfibrozil, are reviewed at each visit; cyclosporine is contraindicated and gemfibrozil limits rosuvastatin to 10 mg daily. Annual cardiovascular risk reassessment using current calculators ensures the chosen intensity remains appropriate as risk evolves.

Special Populations

Asian patients begin at 5 mg daily because of higher systemic exposure. In renal impairment with eGFR less than 30 mL/min and not on hemodialysis, the starting dose is 5 mg with a maximum of 10 mg, and the 40 mg dose is contraindicated. Active liver disease and unexplained persistent transaminase elevations contraindicate use. Pregnancy and lactation are contraindications because cholesterol is essential for fetal development; women of reproductive potential should use effective contraception. Pediatric use is approved for heterozygous familial hypercholesterolemia in patients 8 years and older, with weight-based starting doses.

Elderly patients require no automatic dose adjustment but are more susceptible to myopathy and drug interactions. Patients on protease inhibitors such as atazanavir-ritonavir or lopinavir-ritonavir should not exceed 10 mg daily. Concurrent fenofibrate carries less interaction risk than gemfibrozil and is preferred when combined fibrate-statin therapy is required for severe mixed dyslipidemia. Patients with prior immune-mediated necrotizing myopathy on any statin should not be rechallenged. Hypothyroidism should be corrected before judging statin tolerance because untreated hypothyroidism alone produces myalgia and elevated CK. Heavy alcohol use raises the risk of hepatic side effects and is discussed at every visit. Patients on warfarin should have INR monitored more closely when initiating, stopping, or adjusting rosuvastatin doses.

When to Contact Your Doctor

Call the office promptly for new muscle pain, tenderness, or weakness, especially if accompanied by dark cola-colored urine, unusual fatigue, or fever - these may signal myopathy or rhabdomyolysis. Yellowing of the skin or eyes, persistent nausea, abdominal pain, or unusual bruising can suggest hepatotoxicity. Pregnancy or planning pregnancy requires discontinuation. New diabetes symptoms - increased thirst, frequent urination, blurred vision - deserve evaluation. Severe allergic reactions including rash, swelling, or breathing difficulty warrant emergency care. Sudden vision changes, slurred speech, or one-sided weakness require 911 activation regardless of cause.

If you would like to review your statin regimen or cardiovascular risk profile, contact us or schedule a visit with our internal medicine team.